vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the best hot stocks to buy according to analysts. On March 10, vTv Therapeutics reported its financial results for Q4 and the full-year 2025. For 2025, the company reported a net loss of $27.0 million, with R&D expenses rising to $17.9 million due to increased investment in clinical trials for cadisegliatin. The company also highlighted advancements in the development of cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes.
Throughout 2025, the company initiated patient dosing in the Phase 3 CATT1 trial and successfully expanded its scientific advisory board with internationally recognized experts. Despite a slower-than-expected start to patient recruitment, vTv Therapeutics Inc. (NASDAQ:VTVT) increased its clinical site count and engagement efforts, leading to accelerated enrollment momentum. The company now expects to complete enrollment for the CATT1 trial in Q3 2026.
There was a notable expansion of a licensing agreement with Newsoara Biopharma Inc. in February. This amendment granted Newsoara exclusive worldwide rights to vTv’s PDE4 inhibitor, HPP737, in exchange for a $20.0 million upfront payment and potential future milestones totaling up to $115 million plus royalties. Additionally, vTv Therapeutics broadened the scope of cadisegliatin by submitting a Phase 2 clinical study protocol to the Abu Dhabi Department of Health to evaluate the therapy’s efficacy and safety in patients with type 2 diabetes, marking a key step in its international research efforts.
Copyright: paylessimages / 123RF Stock Photo
vTv Therapeutics Inc. (NASDAQ:VTVT) is a late-stage biopharmaceutical company that develops oral small-molecule drug candidates intended to treat people living with diabetes and other chronic diseases.
While we acknowledge the potential of VTVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
